Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan

Molecular Pharmacology

Volumn 73, Issue 2, 2008, Pages 490-497

  Liao, Zhiyong ^a   Robey, Robert W ^a   Guirouilh Barbat, Josée ^a   To, Kenneth K W ^a   Polgar, Orsolya ^a   Bates, Susan E ^a   Pommier, Yves ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DIFLOMOTECAN; DNA TOPOISOMERASE; ETOPOSIDE; GLYCOPROTEIN P; HOMOCAMPTOTHECIN; ISOQUINOLINE DERIVATIVE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

CAMPTOTHECIN; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; DOWN-REGULATION; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLIOBLASTOMA; HUMANS;

EID: 38549161260     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041178     Document Type: Article

References (40)

1. Bailly C, Lansiaux A, Dassonneville L, Demarquay D, Coulomb H, Huchet M, Lavergne O, and Bigg DC (1999) Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry 38:15556-15563.
2. Bates SE, Medina-Perez WY, Kohlhagen G, Antony S, Nadjem T, Robey RW, and Pommier Y (2004) ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins. J Pharmacol Exp Ther 310:836-842.
3. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, and Bates SE (1999) Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59:5938-5946.
4. Calvet L, Santos A, Valent A, Terrier-Lacombe MJ, Opolon P, Merlin JL, Aubert G, Morizet J, Schellens JH, Benard J, et al. (2004) No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. Br J Cancer 91:1205-1212.
5. Chamberlain MC (2002) Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 56:183-188.
6. Chamberlain MC (2006) Treatment options for glioblastoma. Neurosurg Focus 20:E2.
7. Chauvier D, Morjani H, and Manfait M (2002) Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells. Breast Cancer Res Treat 73:113-125.
8. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, and Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044.
9. Chen ZS, Furukawa T, Sumizawa T, Ono K, Ueda K, Seto K, and Akiyama SI (1999) ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol 55:921-928.
10. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, and Elfring GL (2003) Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 97(9 Suppl):2381-2386.
11. Eng WK, McCabe FL, Tan KB, Mattern MR, Hofmann GA, Woessner RD, Hertzberg RP, and Johnson RK (1990) Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38:471-480.
12. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, et al. (1999) Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516-1525.
13. Fujimori A, Gupta M, Hoki Y, and Pommier Y (1996a) Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 50:1472-1478.
14. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, and Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res 55:1339-1346.
15. Fujimori A, Hoki Y, Popescu NC, and Pommier Y (1996b) Silencing and selective methylation of the normal topoisomerase I gene in camptothecin- resistant CEM/C2 human leukemia cells. Oncol Res 8:295-301.
16. Gelderblom H, Salazar R, Verweij J, Pentheroudakis G, de Jonge MJ, Devlin M, van Hooije C, Seguy F, Obach R, Prunonosa J, et al. (2003) Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin Cancer Res 9:4101-4107.
17. Hoki Y, Fujimori A, and Pommier Y (1997) Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 40:433-438.
18. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, et al. (2001) Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 280:1216-1223.
19. Kohn KW (1996) DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 18:505-513.
20. Larsen AK, Gilbert C, Chyzak G, Plisov SY, Naguibneva I, Lavergne O, Lesueur-Ginot L, and Bigg DC (2001) Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res 61:2961-2967.
21. Lavergne O, Demarquay D, Bailly C, Lanco C, Rolland A, Huchet M, Coulomb H, Muller N, Baroggi N, Camara J, et al. (2000a) Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J Med Chem 43:2285-2289.
22. Lavergne O, Demarquay D, Kasprzyk PG, and Bigg DC (2000b) Homocamptothecins: E-ring modified CPT analogues. Ann N Y Acad Sci 922:100-111.
23. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, and Schellens JH (1999) Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59:4559-4563.
24. Parney IF and Chang SM (2003) Current chemotherapy for glioblastoma. Cancer J 9:149-156.
25. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802.
26. Pommier Y, Barcelo JM, Rao VA, Sordet O, Jobson AG, Thibaut L, Miao ZH, Seiler JA, Zhang H, Marchand C, et al. (2006) Repair of topoisomerase I-mediated DNA damage. Prog Nucleic Acid Res Mol Biol 81:179-229.
27. Pommier Y, Pourquier P, Urasaki Y, Wu J, and Laco GS (1999) Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 2:307-318.
28. Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, and Pommier Y (2000) Induction of topoisomerase I cleavage complexes by 1-β-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A 97:1885-1890.
29. Rajendra R, Gounder MK, Saleem A, Schellens JH, Ross DD, Bates SE, Sinko P, and Rubin EH (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res 63:3228-3233.
30. Robey RW, Fetsch PA, Polgar O, Dean M, and Bates SE (2006) The livestock photosensitizer, phytoporphyrin (phylloerythrin), is a substrate of the ATP-binding cassette transporter ABCG2. Res Vet Sci 81:345-349.
31. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, and Bates SE (2001a) A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 1512:171-182.
32. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, and Bates SE (2001b) Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 7:145-152.
33. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246.
34. Schneider E, Horton JK, Yang CH, Nakagawa M, and Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152-158.
35. Tan KB, Mattern MR, Eng WK, McCabe FL, and Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81:1732-1735.
36. Troconiz IF, Garrido MJ, Segura C, Cendros JM, Principe P, Peraire C, and Obach R (2006) Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother Pharmacol 57:727-735.
37. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, and Pommier Y (2001) Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 61:1964-1969.
38. Urasaki Y, Takebayashi Y, and Pommier Y (2000) Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations. Cancer Res 60:6577-6580.
39. Vassal G, Doz F, Frappaz D, Imadalou K, Sicard E, Santos A, O'Quigley J, Germa C, Risse ML, Mignard D, et al. (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852.
40. Yanase K, Sugimoto Y, Tsukahara S, Oh-Hara T, Andoh T, and Tsuruo T (2000) Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma. Jpn J Cancer Res 91:551-559.